Art. -Nr.: HY-B0481

Miglitol

(Synonyms: BAY1099; BAY-m1099)

3 Cited Publications

Kundenbewertung

Based on 3 publication(s) in Google Scholar

Miglitol (BAY-m1099) is an orally active antidiabetic compound that inhibits the breakdown of glycoconjugates into glucose. Miglitol inhibits glycoside hydrolase enzymes called α-glucosidases. Miglitol inhibits oxidative stress-induced apoptosis and mitochondrial ROS over-production in endothelial cells by enhancement of AMP-activated protein kinase. Dietary supplementation with Miglitol from pre-onset stage in OLETF rats delays the onset and development of diabetes and preserves the insulin secretory function of pancreatic islets.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.95%
CAS. Nr.: 72432-03-2
Formel: C₈H₁₇NO₅
Molecular Weight:207.22

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Miglitol Chemical Structure

CAS. Nr.: 72432-03-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (3)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle AMPK Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
Caco-2	IC₅₀	1 μM Compound: 5	Inhibition of maltase in human Caco-2 cell model system after 2 hrs Inhibition of maltase in human Caco-2 cell model system after 2 hrs	[PMID: 18595718]

In Vitro

Miglitol (100-500 μM, 24 h) reduces endothelial cell injury in response to H₂O₂, exists cytoprotective effects against oxidative stress by H₂O₂ in bEnd.3 cells^[4].
Miglitol (100-500 μM, 0-15 min) activates AMPK and induces eNOS activity and NO production in endothelial cells^[4].
Miglitol (100-500 μM, 24 h) inhibits VCAM-1 and ICAM-1 mRNA expression and improves endothelial function in rats^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[4]

Cell Line:

bEnd.3 cells
Concentration:

100-500 μM
Incubation Time:

24 h
Result:

Attenuated the bEnd.3 cell injury in response to H₂O₂, decreased cellular ROS production, reduced DNA injury and the activation of the nuclear enzyme poly (ADP-ribose) polymerase (PARP).

Western Blot Analysis^[4]

Cell Line:

bEnd.3 cells
Concentration:

100-500 μM
Incubation Time:

0-15 min
Result:

Resulted in time-dependent activation of AMPK, increased Akt phosphorylation (Ser-473) and eNOS phosphorylation (Ser-1177) and activation.

In Vivo

Miglitol (800 ppm, mixed in the diet, daily for 65 weeks) delays the onset and development of diabetes and preserves the insulin secretory function of pancreatic islets in Otsuka Long-Evans Tokushima Fatty (OLETF) rats^[1].
Miglitol (40 mg, mixed in the diet, daily for 29 days) decreases the body weight level, the postprandial plasma glucose level, the levels of plasma glucose and glycoalbumin, and elevates the level of HDL-C in fatty rats^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

OLETF rats^[1]
Dosage:

800 ppm
Administration:

mixed in the diet, daily for 65 weeks
Result:

Significantly increased the ΔAUC0-3 h of plasma insulin, HbA1c concentrations and decreased the size of the fibrous area/islets in OLETF rats.

Animal Model:

Fatty rats^[2]
Dosage:

40 mg
Administration:

mixed in the diet, daily for 29 days
Result:

Insignificantly decreased the body weight level on days 15 and 29 and significantly decreased the postprandial plasma glucose level, the levels of plasma glucose and glycoalbumin, and elevated the level of HDL-C in fatty rats.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 72432-03-2
Appearance Solid
Molecular Weight 207.22
Formel C₈H₁₇NO₅
Color White to yellow
SMILES

O[C@@H]1[C@@H](CO)N(CCO)C[C@H](O)[C@H]1O
Synonyms

BAY1099; BAY-m1099
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (3)

All

Sort by:

Journal Impact Factor

J Asian Nat Prod Res

Biotransformation and activity identification of icariin in human intestinal fungus Pichia occidentalis. [Abstract]

2025 May 21:1-12. PMID: 40396926
University of Maryland

2026.
SSRN

2025 Jul 25.

Lösungsmittel & Löslichkeit

In Vitro:

H₂O : ≥ 200 mg/mL (965.16 mM)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.8258 mL

24.1289 mL

48.2579 mL

5 mM

0.9652 mL

4.8258 mL

9.6516 mL

10 mM

0.4826 mL

2.4129 mL

4.8258 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 100 mg/mL (482.58 mM); Clear solution; Need ultrasonic

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Fukaya, N., et al., The alpha-glucosidase inhibitor miglitol delays the development of diabetes and dysfunctional insulin secretion in pancreatic beta-cells in OLETF rats. Eur J Pharmacol, 2009. 624(1-3): p. 51-7. [Content Brief]

[2]. Hirata, A., et al., Effect of miglitol, an alpha-glucosidase inhibitor, on atherogenic outcomes in balloon-injured diabetic rats. Horm Metab Res, 2009. 41(3): p. 213-20. [Content Brief]

[3]. Scott LJ, et al. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. Drugs. 2000 Mar;59(3):521-49. [Content Brief]

[4]. Aoki C, et al. Miglitol, an anti-diabetic drug, inhibits oxidative stress-induced apoptosis and mitochondrial ROS over-production in endothelial cells by enhancement of AMP-activated protein kinase. J Pharmacol Sci. 2012;120(2):121-8. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	4.8258 mL	24.1289 mL	48.2579 mL	120.6447 mL
	5 mM	0.9652 mL	4.8258 mL	9.6516 mL	24.1289 mL
	10 mM	0.4826 mL	2.4129 mL	4.8258 mL	12.0645 mL
	15 mM	0.3217 mL	1.6086 mL	3.2172 mL	8.0430 mL
	20 mM	0.2413 mL	1.2064 mL	2.4129 mL	6.0322 mL
	25 mM	0.1930 mL	0.9652 mL	1.9303 mL	4.8258 mL
	30 mM	0.1609 mL	0.8043 mL	1.6086 mL	4.0215 mL
	40 mM	0.1206 mL	0.6032 mL	1.2064 mL	3.0161 mL
	50 mM	0.0965 mL	0.4826 mL	0.9652 mL	2.4129 mL
	60 mM	0.0804 mL	0.4021 mL	0.8043 mL	2.0107 mL
	80 mM	0.0603 mL	0.3016 mL	0.6032 mL	1.5081 mL
	100 mM	0.0483 mL	0.2413 mL	0.4826 mL	1.2064 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Miglitol

3 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Miglitol

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

FDA-Approved Drug Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Lipid Metabolism Compound Library

Glucose Metabolism Compound Library

Human Metabolite Library

Heterocyclic Compound Library

Pain-Related Compound Library

Off-patent Drug Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Miglitol

Alle AMPK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (3)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Miglitol Related Classifications

HY-B0481 Related Classifications